Equilis Prequenza Te

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
10-12-2020
Toote omadused Toote omadused (SPC)
10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
23-05-2013

Toimeaine:

equine influenza-virus strains: A/equine-2/South Africa/4/03, A/equine-2/Newmarket/2/93, tetanus toxoid

Saadav alates:

Intervet International BV

ATC kood:

QI05AL01

INN (Rahvusvaheline Nimetus):

vaccine against equine influenza and tetanus in horses

Terapeutiline rühm:

Horses

Terapeutiline ala:

equine influenza virus + clostridium

Näidustused:

Active immunisation of horses from six months of age against equine influenza to reduce clinical signs and virus excretion after infection, and active immunisation against tetanus to prevent mortality.

Toote kokkuvõte:

Revision: 10

Volitamisolek:

Authorised

Loa andmise kuupäev:

2005-07-08

Infovoldik

                                14
B.
PACKAGE LEAFLET
15
PACKAGE LEAFLET:
Equilis Prequenza Te suspension for injection for horses
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE,
IF DIFFERENT
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza Te suspension for injection for horses
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
Each dose of 1 ml contains:
ACTIVE SUBSTANCES
Equine influenza virus strains:
A/equine-2/ South Africa/4/03 50 AU
1
A/equine-2/ Newmarket/2/93
50 AU
Tetanus toxoid
40 Lf
2
1
Antigenic ELISA units
2
Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig
serum in the Ph.Eur. potency test
ADJUVANT
Iscom Matrix containing:
Purified saponin
375 micrograms
Cholesterol
125 micrograms
Phosphatidylcholine
62.5 micrograms
Clear opalescent suspension.
4.
INDICATION(S)
Active immunisation of horses from 6 months of age against equine
influenza to reduce clinical signs and virus
excretion after infection, and active immunisation against tetanus to
prevent mortality.
Influenza
Onset of immunity:
2 weeks after the primary vaccination course
Duration of immunity:
5 months after the primary vaccination course
12 months after the first revaccination
Tetanus
Onset of immunity:
2 weeks after the primary vaccination course
16
Duration of immunity:
17 months after the primary vaccination course
24 months after the first revaccination
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
A diffuse hard or soft swelling (max. diameter 5 cm) may rarely occur
at the injection site, regressing within
2 days. Pain at the injection site can occur in rare cases which may
result in temporary functional discomfort
(stiffness). A local reaction exceeding 5 cm and possibly persisting
longer than 2 days may occur in very rare
cases. Fever, sometimes accompanied by lethargy and inappetence, may
in very rare cases occur for 1 day,
and up to 3 days in exceptio
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza Te suspension for injection for horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
ACTIVE SUBSTANCES:
Equine influenza virus strains:
A/equine-2/ South Africa/4/03
50 AU
1
A/equine-2/ Newmarket/2/93
50 AU
Tetanus toxoid
40 Lf
2
1
Antigenic units
2
Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig
serum in the Ph.Eur. potency test
ADJUVANTS:
Iscom-Matrix containing:
Purified Saponin
375 micrograms
Cholesterol
125 micrograms
Phosphatidylcholine
62.5 micrograms
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Clear opalescent suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of horses from 6 months of age against equine
influenza to reduce clinical signs and virus
excretion after infection, and active immunisation against tetanus to
prevent mortality.
Influenza
Onset of immunity:
2 weeks after the primary vaccination course
Duration of immunity:
5 months after the primary vaccination course
12 months after the first revaccination
Tetanus
Onset of immunity:
2 weeks after the primary vaccination course
Duration of immunity:
17 months after the primary vaccination course
24 months after the first revaccination
4.3
CONTRAINDICATIONS
3
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Foals should not be vaccinated before the age of 6 months, especially
when born to mares that were
revaccinated in the last two months of gestation, because of possible
interference by maternally derived
antibodies.
Vaccinate healthy animals only.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or the
label to the ph
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 10-12-2020
Toote omadused Toote omadused bulgaaria 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 23-05-2013
Infovoldik Infovoldik hispaania 10-12-2020
Toote omadused Toote omadused hispaania 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 23-05-2013
Infovoldik Infovoldik tšehhi 10-12-2020
Toote omadused Toote omadused tšehhi 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 23-05-2013
Infovoldik Infovoldik taani 10-12-2020
Toote omadused Toote omadused taani 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande taani 23-05-2013
Infovoldik Infovoldik saksa 10-12-2020
Toote omadused Toote omadused saksa 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande saksa 23-05-2013
Infovoldik Infovoldik eesti 10-12-2020
Toote omadused Toote omadused eesti 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande eesti 23-05-2013
Infovoldik Infovoldik kreeka 10-12-2020
Toote omadused Toote omadused kreeka 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 23-05-2013
Infovoldik Infovoldik prantsuse 10-12-2020
Toote omadused Toote omadused prantsuse 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 23-05-2013
Infovoldik Infovoldik itaalia 10-12-2020
Toote omadused Toote omadused itaalia 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 23-05-2013
Infovoldik Infovoldik läti 10-12-2020
Toote omadused Toote omadused läti 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande läti 23-05-2013
Infovoldik Infovoldik leedu 10-12-2020
Toote omadused Toote omadused leedu 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande leedu 23-05-2013
Infovoldik Infovoldik ungari 10-12-2020
Toote omadused Toote omadused ungari 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande ungari 23-05-2013
Infovoldik Infovoldik malta 10-12-2020
Toote omadused Toote omadused malta 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande malta 23-05-2013
Infovoldik Infovoldik hollandi 10-12-2020
Toote omadused Toote omadused hollandi 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 23-05-2013
Infovoldik Infovoldik poola 10-12-2020
Toote omadused Toote omadused poola 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande poola 23-05-2013
Infovoldik Infovoldik portugali 10-12-2020
Toote omadused Toote omadused portugali 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande portugali 23-05-2013
Infovoldik Infovoldik rumeenia 10-12-2020
Toote omadused Toote omadused rumeenia 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 23-05-2013
Infovoldik Infovoldik slovaki 10-12-2020
Toote omadused Toote omadused slovaki 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 23-05-2013
Infovoldik Infovoldik sloveeni 10-12-2020
Toote omadused Toote omadused sloveeni 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 23-05-2013
Infovoldik Infovoldik soome 10-12-2020
Toote omadused Toote omadused soome 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande soome 23-05-2013
Infovoldik Infovoldik rootsi 10-12-2020
Toote omadused Toote omadused rootsi 10-12-2020
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 23-05-2013
Infovoldik Infovoldik norra 10-12-2020
Toote omadused Toote omadused norra 10-12-2020
Infovoldik Infovoldik islandi 10-12-2020
Toote omadused Toote omadused islandi 10-12-2020
Infovoldik Infovoldik horvaadi 10-12-2020
Toote omadused Toote omadused horvaadi 10-12-2020

Vaadake dokumentide ajalugu